Introduction {#s0005}
============

Colorectal cancer accounts for more than 9% of all cancer incidences and is the third most common cancer reported worldwide, as well as being the fourth most common cause of death [@bb0005]. More than half of colorectal cancer patients will develop liver metastases during the course of the disease [@bb0010]. Colorectal cancer liver metastasis (CRLM) is the leading cause of death in patients with colorectal cancer [@bb0015]. Liver resection is the gold standard treatment for CRLM patients and confers the best prognosis [@bb0020], [@bb0025]. However, liver resection is associated with significant mortality and morbidity, due to major complications such as liver failure, blood loss and bile leak. Post-operative complications have a reported prevalence of 4% to 53% [@bb0030], [@bb0035], [@bb0040]. In addition, the post-operative 5-year survival rates are only 30% to 50% [@bb0015] and more than 70% of patients will have a recurrence after resection for CRLM [@bb0045]. Therefore, it is crucial to explore and identify biomarkers that are affordable and technically feasible for predicting post-operative major complications and survival at earlier time points in CRLM patients.

Gamma-glutamyltransferase (GGT) is a membrane bound enzyme that is involved in glutathione (GSH) metabolism [@bb0050]. Some studies [@bb0055], [@bb0060], [@bb0065] have demonstrated that GGT modulated the cellular proliferative and apoptotic balance and played an important role in tumor progression, invasion and drug resistance. Recently, pre-operative serum GGT levels have been linked to several human malignancies, including hepatocellular carcinoma (HCC), esophageal squamous cell carcinoma, ovarian cancer and renal cell carcinoma, with GGT acting as a negative prognostic marker [@bb0070], [@bb0075], [@bb0080], [@bb0085]. For liver disease, GGT is predominantly used as a diagnostic marker. Latent elevations in GGT are seen to be related to specific pathologies such as liver fibrosis with HBV infection, non-alcoholic fatty liver disease, alcoholic liver disease and other chronic liver disease [@bb0090], [@bb0095], [@bb0100].

Recent studies suggested a process of hemostasis and fibrinolysis was related to tumor angiogenesis, invasion, progression, and metastatic spread [@bb0105]. D-dimer, one of the key components in the activation of hemostasis and fibrinolysis, has been found to be associated with poor prognosis in several malignant diseases, including lung cancer, ovarian cancer and gastric cancer [@bb0110], [@bb0115], [@bb0120], [@bb0125]. For liver disease, the increased D-dimer correlated well with the higher Child-Pugh scores indicating the aggravation of hepatic impairment. Elevated plasma values of D-dimer in patients with liver cirrhosis are risk factors for a higher incidence in decompensated liver disease and portal vein thrombosis [@bb0130], [@bb0135].

There has not been a study examining the prognostic significance of serum D-dimer levels and GGT levels in CRLM. In view of the characteristics of these two biomarkers, we speculate that these two biomarkers are of great value in predicting the prognosis of CRLM. The aim of the present study was to explore the association between pre-operative D-dimer levels and GGT levels and prognoses in CRLM patients after liver resection.

Materials and Methods {#s0010}
=====================

Patients {#s0015}
--------

Two hundred and ninety-two patients who were admitted to our hospital between December 2008 and December 2016 were identified as a training set. One hundred and one patients at our center from January 2017 to December 2018 were selected as a validation set. This study was approved by the Institutional Review Board of the Cancer Institute & Hospital, Chinese Academy of Medical Sciences.

The inclusion criteria were as follows: (1) the primary tumor site was removed and pathologically diagnosed as colorectal cancer; (2) patients were diagnosed with liver metastasis from colorectal cancer by post-operative pathology; and (3) patients were treated with resection for CRLM, according to the guidelines for the treatment of CRLM [@bb0015]. Extrahepatic disease (EHD) was not a contraindication for surgery as long as all of the EHD sites could be radically treated (surgery, radiotherapy, ablation, etc.). Data on patient demographics, clinicopathological characteristics and medical treatment were reviewed.

Patients were not eligible if they presented with pre-treatment comorbidities known to be associated with elevated GGT (i.e. biliary tract-, pancreatic- and heart disease or alcohol abuse) and D-dimer (i.e. deep venous thrombosis, pulmonary embolism or disseminated intravascular coagulation).

Measurement of Serum GGT Levels and D-dimer Levels {#s0020}
--------------------------------------------------

Serum GGT levels and D-dimer levels were measured within 1 week before surgery. Blood samples for the evaluation of serum GGT levels and D-dimer levels were obtained by using peripheral venous punctures. Serum GGT concentrations were analyzed with an enzyme kinetic assay (Roche Diagnostics GmbH, Mannheim, Germany). The normal value range of the GGT levels was between 0 and 55 U/L in our hospital. Serum D-dimer concentrations were analyzed with an enzyme-linked fluorescent immunoassay method. The normal value range of the D-dimer levels was between 0 and 0.55 mg/L in our hospital.

To analyze the prognostic value of the combination of the pre-operative D-dimer with GGT levels (CPDG) in major complications and survival, we created a CPDG score construct based on the D-dimer levels and GGT levels. The CPDG score was scored as follows: elevated D-dimer levels with elevated GGT levels was allocated a score of 2, decreased D-dimer levels with decreased GGT levels was allocated a score of 0, and all other combinations were allocated a score of 1.

Treatment {#s0025}
---------

As described previously [@bb0140], decisions about the treatment of CRLM were reached by the consensus of a multidisciplinary team (MDT) including surgeons, oncologists and radiologists. Pre-operative chemotherapy was recommended to patients with initially unresectable liver metastases or to patients with multiple high-risk factors [@bb0145], [@bb0150]. Chemotherapy was mainly comprised of a combination of 5-fluorouracil/capecitabine and oxaliplatin/irinotecan, with or without bevacizumab and cetuximab. Surgical resections included the open and laparoscopic approaches. The resection margin status was defined according to the International Union Against Cancer (UICC) criteria. Liver resections were divided into major and minor resections. Major resections were defined as resections of more than two segments, and other resections were described as being minor resections. Intraoperative RFA was used when a hepatic lesion was located more deeply or proximal to major vascular structures and was especially used for lesions that were less than 3 cm.

Follow-Up and Endpoints {#s0030}
-----------------------

Patients were followed up at regular intervals. The initial post-treatment CT and MRI scans occurred one month after surgery. Afterwards, patients were followed up at 3-month intervals for up to 2 years and every 6 months thereafter. All post-operative complications were graded according to the Clavien-Dindo classification system [@bb0025]. Minor complications were classified as Clavien-DindoI-II, and major complications were classified as Clavien-Dindo III -V. Overall survival (OS) was defined as the length of time from the date of hepatic resection for liver metastasis to the last follow-up or death. Progression-free survival (PFS) was defined as the interval between hepatic resection for liver metastasis and a recurrence or progression of the (residual) disease.

Statistical Analysis {#s0035}
--------------------

Data were compared using Fisher\'s exact tests for the categorical variables and the non-parametric Mann-Whitney *U* tests for the continuous variables. A ROC curve was constructed to estimate the predictive value of the pre-operative GGT levels and D-dimer levels. The optimal cutoff values were identified using the highest Youden index (sensitivity+specificity-1) [@bb0155]. Prediction accuracy was evaluated with the area under the ROC curve. All predictors with *P* \< .10 by univariate analysis were retained in the multivariate model. A multivariate logistic regression analysis was performed to identify independent factors. A Kaplan-Meier survival analysis was used to calculate OS and PFS, and significant differences between the groups were evaluated by using the log-rank test. Multivariable analyses of OS and PFS were performed by using Cox regression models. Finally, we will verify the findings in the validation cohort. A difference of *P* \< .05 was statistically significant. Statistical analyses were performed using the SPSS, version 22 software (Armonk NV, USA).

Results {#s0040}
=======

Patient and Tumor Characteristics {#s0045}
---------------------------------

The clinicopathological characteristics for the training set (n = 292) and validation set (n = 101) are listed in [Table 1](#t0005){ref-type="table"}, [Table 2](#t0010){ref-type="table"}. Of the 393 patients analyzed, 154 (39.2%) were female and 239 (60.8%) were male and the median age (interquartile range \[IQR\]) was 57.0 (50.0-63.5) years. A total of 45 patients (11.5%) presented with extrahepatic metastases at the initial diagnosis. As to the tumors located in the liver, synchronous metastasis was detected in 235 (80.5%) and 70 (69.3%) patients in the training set and validation set, respectively. Liver lesions located in both lobes of liver were detected in 142 (36.1%) patients. Preoperative chemotherapy was given to 240 (60.1%) patients in the whole cohort. As to the primary site, it was located in the colon among patients in 156 (53.4%) patients from the training set and 58 (57.4%) patients from the validation set and was located in the rectum for other patients. All included patients had received hepatectomy, among which major hepatectomy, heterochronous resection, and RFA was performed in 184 (46.8%), 148 (37.7%), and 44 (11.2%) patients, respectively. R0 resection was achieved in 258 (65.6%) patients.Table 1Patients' characteristics of the training set and validation setTable 1ItemTraining set\
(*n* = 292) (%)Validation set\
(*n* = 101) (%)Age ≥60 years108 (37.0)45 (44.6)Female114 (39.0)40 (39.6)Preoperative CEA ≥10 ng/ml130 (44.5)43 (42.6)Major resection124 (42.5)60 (59.4)Synchronous metastasis235 (80.5)70 (69.3)Primary site colon156 (53.4)58 (57.4)Left hemicolon45 (15.4)19 (18.8)Pretreatment chemotherapy186 (63.6)54 (53.5)R0 resection195 (66.8)63 (62.4)RFA36 (12.3)8 (7.92)Bilobar distribution111 (38.0)31 (30.7)Extrahepatic metastases26 (8.90)19 (18.8)Diameter of metastases ≥3 cm138 (47.3)45 (44.6)Multiple metastases171 (58.6)44 (43.6)Operation time ≥ 301.5 min127 (43.5)38 (37.6)Poorly differentiated69 (23.6)29 (28.7)T3-T4243 (83.2)82 (81.1)Heterochronous resection113 (38.7)35 (34.7)Table 2Patient and tumor characteristics in the training setTable 2ItemD-dimer﹤0.285\
(n = 116) (%)D-dimer ≥ 0.285\
(n = 176) (%)*P*GGT﹤30.5\
(n = 144) (%)GGT ≥30.5\
(n = 148) (%)*P*CPDG = 0 (n = 66) (%)CPDG = 1 (n = 128) (%)CPDG = 2 (n = 98) (%)*P*All patients\
(n = 292) (%)Age ≥60 years37 (31.9)71 (40.3)0.14459 (41.0)49 (33.1)0.16422 (33.3)52 (40.6)34 (34.7)0.515108 (37.0)Female43 (37.1)71 (40.3)0.57563 (43.8)51 (34.5)0.10424 (36.4)58 (45.3)32 (32.7)0.136114 (39.0)Preoperative CEA ≥10 ng/ml45 (38.8)85 (48.3)0.11058 (40.3)72 (48.6)0.15024 (36.4)55 (43.0)51 (52.0)0.126130 (44.5)Major resection37 (31.9)87 (49.4)0.00337 (25.7)87 (38.8)\<0.00111 (16.7)52 (40.6)61 (62.2)\<0.001124 (42.5)Synchronous metastasis87 (75.0)148 (84.1)0.055118 (81.9)117 (79.1)0.53350 (75.8)105 (82.0)80 (81.6)0.544235 (80.5)Primary site Colon61 (52.6)95 (54.0)0.81676 (52.8)80 (54.1)0.82735 (53.0)67 (52.3)54 (55.1)0.916156 (53.4)Left hemicolon16 (13.8)29 (16.5)0.53429 (20.1)16 (10.8)0.02713 (19.7)19 (14.8)13 (13.3)0.52045 (15.4)Pretreatment chemotherapy53 (45.7)133 (75.6)\<0.00178 (54.2)108 (73.0)0.00125 (37.9)81 (63.3)80 (81.6)\<0.001186 (63.7)R0 resection80(69.0)115 (65.3)0.520103 (71.5)92 (62.2)0.08947 (71.2)89 (69.5)59 (60.2)0.231195 (66.8)RFA7 (6.0)29 (16.5)0.00812 (8.3)24 (16.2)0.0415 (7.6)9 (7.0)22 (22.4)0.00136 (12.3)Bilobar distribution30 (25.9)81 (46.0)0.00136 (25.0)75 (50.7)\<0.00113 (19.7)40 (31.3)58 (59.2)\<0.001111 (38.0)Extrahepatic metastases11 (9.5)15 (8.5)0.77811 (7.6)15 (10.1)0.4544 (6.1)14 (10.9)8 (8.2)0.50226 (8.9)Diameter of metastases ≥3 cm48 (41.4)90 (51.1)0.10256 (38.9)82 (55.4)0.00524 (36.4)56 (43.8)58 (59.2)0.009138 (47.3)Multiple metastases56 (48.3)115 (65.3)0.00464 (44.4)107 (72.3)\<0.00126 (39.4)68 (53.1)77 (78.6)\<0.001171 (58.6)Operation time ≥ 301.5 min34 (29.3)92 (52.3)\<0.00148 (33.3)78 (52.7)0.00116 (24.2)50 (39.1)60 (61.2)\<0.001126 (43.2)Poorly differentiated27 (23.3)42 (23.9)0.90829 (20.1)40 (27.0)0.16616 (24.2)24 (18.8)29 (29.6)0.16369 (23.6)T1-T213 (11.2)36 (20.5)0.03917 (11.8)32 (21.6)0.0258 (12.1)14 (10.9)27 (27.6)0.00249 (16.8)Heterochronous resection52 (44.8)61 (34.7)0.08150 (34.7)63 (42.6)0.16926 (39.4)50 (39.1)37 (37.8)0.972113 (38.7)

Predictors for Post-Operative Major Complications in the Training Set {#s0050}
---------------------------------------------------------------------

Major complications occurred in 43 (14.7%) and 25 (24.8%) patients in the training set and validation set, respectively.

ROC curves illustrating the ability of the pre-operative D-dimer levels and GGT levels to predict post-operative major complications were performed in the training set. For D-dimer levels, the optimal cutoff level was 0.485 mg/L, and the area under the curve (AUC) was 0.661 (95%CI: 0.572-0.750, *P* = .001). This value was associated with a sensitivity of 0.651 and a specificity of 0.671 (negative predictive value \[NPV\]: 0.918; positive predictive value \[PPV\]: 0.561). One hundred and eighty-two patients (62.3%) had a D-dimer \<0.485 mg/L, and 110 patients (37.7%) had a D-dimer ≥0.485 mg/L. For GGT levels, the optimal cutoff level was 35.5 U/L, and the AUC was 0.645 (95%CI: 0.556-0.734, *P* = .002). This value was associated with a sensitivity of 0.651 and a specificity of 0.639 (NPV: 0.914; PPV: 0.461). One hundred and seventy-four patients (59.6%) had a GGT\< 35.5 U/L, and 118 patients (40.4%) had a GGT ≥35.5 U/L.

The predictors for post-operative major complications were analyzed. In the univariate analysis, resection type (*P* = .024), pretreatment chemotherapy (*P* = .009), diameters of metastases (*P* = .011), operation time (*P* = .005), pre-operative GGT levels (*P* \< .001) and pre-operative D-dimer levels (*P* \< .001) were statistically significant parameters. These statistically significant parameters in the univariate analysis were retained in the multivariate model. In the multivariate analysis, elevated pre-operative D-dimer levels (OR = 3.474, 95% CI: 1.736-6.949, *P* \< .001) and elevated pre-operative GGT levels (OR = 2.977, 95% CI: 1.486-5.965, *P* = .002) significantly predicted the major complications ([Table 3](#t0015){ref-type="table"}).Table 3Prognostic factors for major complications in CRLM patients after surgery in the training setTable 3FactorUnivariate analysisMultivariate analysis*P*OR (95%CI)*P*Age ≥60 years0.290Sex (male vs. female)0.790Preoperative CEA ≥10 ng/ml0.169Major resection0.024Synchronous metastasis0.278Primary site colon0.734Left hemicolon0.530Pretreatment chemotherapy0.009R0 resection0.547Extrahepatic metastases0.208Bilobar distribution0.574Diameter of metastases ≥3 cm0.011Multiple metastases0.345Poorly differentiated0.652T3-T40.094Operation time ≥ 301.5 min0.005D-dimer ≥0.485\<0.0013.474 (1.736-6.949)\<0.001GGT ≥35.5 U/L\<0.0012.977 (1.486-5.965)0.002Heterochronous resection0.645  **the prognostic value on CPDG score**CPDG = 2\<0.001Reference-CPDG = 10.112 (0.045-0.276)\<0.001CPDG = 00.198 (0.090-0.432)\<0.001

Predictors for Survival in the Training Set {#s0055}
-------------------------------------------

In the training set, the median follow-up time was 26.3 months. A total of 204 patients (69.86%) experienced disease recurrence, and 102 patients (34.93%) died. The median OS was 49.7 months (95% CI: 38.04-61.36), and the median PFS was 10.1 months (95% CI: 8.16-12.04). The 1-, 3- and 5-year survival rates were 95.20%, 58.80% and 43.30%, respectively. The 1-, 3-year progression-free survival rates were 44.95%, 25.04% respectively. In the validation set, the median follow-up time was 14.0 months. A total of 51 patients (50.5%) experienced disease recurrence, and only 10 patients (9.90%) died due to a short follow-up period. The median PFS was 14.0 months (95% CI: 6.273-21.727) and the median OS was not reached.

Using the median survival time (49.7 months) as an endpoint, ROC curves were constructed to estimate the optimal cutoff value of the pre-operative D-dimer levels and GGT levels for predicting survival. For D-dimer levels, the optimal cutoff level was 0.285 mg/L, and the AUC was 0.688 (95%CI: 0.592-0.784, *P* \< .001). This value was associated with a sensitivity of 0.702 and a specificity of 0.660 (NPV: 0.805; PPV: 0.525). 116 patients (49.67%) had a D-dimer \<0.285 mg/L, and 176 patients (50.33%) had a D-dimer ≥0.285 mg/L. For GGT levels, the optimal cutoff level was 30.5 U/L, and the AUC was 0.676 (95% CI: 0.583-0.768, *P* = .001). This value was associated with a sensitivity of 0.564 and a specificity of 0.787 (NPV: 0.833; PPV: 0.480). One hundred and forty-four144 patients (49.32%) had a GGT \<30.5 U/L, and 148 patients (50.68%) had a GGT ≥30.5 U/L.

The univariate analysis revealed that D-dimer levels ≥0.285 mg/L (*P* = .005), non R0 resection (*P* = .002), bilobar distribution (*P* \< .001), multiple metastases (*P =* .003), operation time ≥301.5 min (*P* = .026) and GGT levels ≥30.5 U/L (*P* = .004) were all associated with decreased OS ([Table 4](#t0020){ref-type="table"}). In the multivariate analysis, elevated pre-operative D-dimer levels (HR = 1.751, 95% CI: 1.139-2.691, *P* = .01), non R0 resection (HR = 1.609, 95%CI: 1.031-2.512, *P* = .036) and a bilobar distribution (HR = 1.672, 95%CI: 1.068-2.620, *P* = .025) remained independently associated with decreased OS ([Table 4](#t0020){ref-type="table"}). When regarding PFS, in the univariate analysis, D-dimer levels ≥0.285 mg/L (HR = 1.455, 95% CI: 1.093-1.937, *P* = .010) and GGT levels ≥30.5 U/L (HR = 1.344, 95%CI: 1.020-1.771, *P* = .036) significantly decreased PFS. In the multivariate analysis, the elevated pre-operative D-dimer levels and elevated pre-operative GGT levels were not independent factors associated with decreased PFS.Table 4Prognostic factors for OS for CRLM patients after surgery in the training setTable 4FactorUnivariate analysisMultivariate analysis*P*HR (95%CI)*P*HR (95%CI)Age ≥60 years0.7641.064 (0.710-1.594)Female0.6601.093 (0.735-1.625)Preoperative CEA ≥10 ng/ml0.1091.374 (0.932-2.028)Major resection0.0011.957 (1.317-2.910)Synchronous metastasis0.0541.716 (0.991-2.971)Primary site Colon0.2911.235 (0.835-1.828)Left hemicolon0.7481.094 (0.632-1.894)Pretreatment chemotherapy0.0731.467 (0.964-2.231)R0 resection0.0020.523 (0.349-0.782)0.0360.621 (0.398-0.970)RFA0.4291.265 (0.706-2.267)Bilobar distribution\<0.0012.157 (1.439-3.232)0.0251.672 (1.068-2.620)Extrahepatic metastases0.1421.571 (0.859-2.872)Diameter of metastases ≥3 cm0.2321.268 (0.859-1.871)Multiple metastases0.0031.882 (1.248-2.837)Poorly differentiated0.9321.022 (0.626-1.667)T3-T40.3631.292 (0.744-2.242)Operation time ≥ 301.5 min0.0261.565 (1.055-2.324)D-dimer ≥0.285 mg/L0.0051.817 (1.193-2.769)0.0111.751 (1.139-2.691)GGT ≥30.5 U/L0.0041.786 (1.199-2.611)Heterochronous resection0.9610.990 (0.666-1.472)  **The prognostic value on CPDG score**CPDG = 2-Reference-ReferenceCPDG = 1\<0.0010.334 (0.187-0.597)0.0020.390 (0.214-0.710)CPDG = 00.0140.198 (0.374-0.894)0.1320.704 (0.446-1.112)

Patients with a D-dimer ≥0.285 mg/L had significantly worse OS and PFS than did patients with a D-dimer \<0.285 mg/L (*P* = .005, mOS: 36.0 months versus 75.9 months; *P* = .005, mPFS: 8.1 months versus 15.0 months) ([Figure 1](#f0005){ref-type="fig"}). Patients with a GGT ≥30.5 U/L had significantly worse OS and PFS than did patients with a GGT \<30.5 U/L (*P* = .004, mOS: 35.2 months versus 70.2 months; *P* = .034, mPFS: 7.5 months versus 12.5 months) ([Figure 1](#f0005){ref-type="fig"}).Figure 1A. Survival analysis of D-dimer \<0.285 mg/L versus D-dimer ≥0.285 mg/L in the training set. B. PFS analysis of D-dimer \<0.285 mg/L versus D-dimer ≥0.285 mg/L in the training set. C. Survival analysis of GGT \<30.5 U/L versus GGT ≥30.5 U/L in the training set. D. PFS analysis of GGT \<30.5 U/L versus GGT ≥30.5 U/L in the training set.Figure 1

Prognostic Value of D-dimer Levels Combined with GGT Levels in the Training Set {#s0060}
-------------------------------------------------------------------------------

In multivariate analysis, two multivariate models were performed separately to account for the fact that the CPDG score is constructed from the D-dimer levels and GGT levels.

In multivariate logistic regression analysis, the CPDG score independently predicted major complications ([Table 3](#t0015){ref-type="table"}). The AUC for the CPDG score was 0.711 (95%CI: 0.622-0.800, *P* \< .001). This value was associated with a sensitivity of 0.588 and a specificity of 0.871 (NPV: 0.908; PPV: 0.550). The AUC for the CPDG score was stronger than the D-dimer levels (*P* = .040, AUC: 0.711 versus 0.661) and GGT levels (*P* = .017, AUC: 0.711 versus 0.645) for predicting major complications in patients with CRLM after liver resection.

For the prediction of survival, in multivariate analysis the CPDG score was an independent prognostic factor for OS and was not an independent factor for PFS ([Table 4](#t0020){ref-type="table"}). The AUC for the CPDG score was 0.760 (95%CI: 0.680-0.840, *P* \< .001). This value was associated with a sensitivity of 0.526 and a specificity of 0.957 (NPV: 0.952; PPV: 0.506). The AUC for the CPDG score was stronger than the D-dimer levels (*P* = .017, AUC: 0.760 versus 0.688) and GGT levels (*P* = .013, AUC: 0.760 versus 0.676) for predicting survival. Kaplan-Meier curve analysis revealed that compared with patients with CPDG = 1 or CPDG = 0, patients with CPDG = 2 were significantly associated with worse OS (*P* \< .001, mOS: 33.8 versus 49.7 months versus 75.9 months, respectively) and worse PFS (*P* = .002, mPFS: 6.3 months versus 12.4 months versus 15.6 months, respectively) ([Figure 2](#f0010){ref-type="fig"}). For OS comparisons, the differences between any two groups were significant (CPDG = 0 versus CPDG = 1, *P* = .049; CPDG = 0 versus CPDG = 2, *P* \< .001; CPDG = 1 versus CPDG = 2, *P* = .019).Figure 2A. Survival analysis of CPDG = 0 versus CPDG = 1 versus CPDG = 2 in the training set . B. PFS analysis of CPDG = 0 versus CPDG =1 versus CPDG = 2 in the training set.Figure 2

Associations of D-dimer, GGT and CPDG with Clinicopathological Characteristics in the Training Set {#s0065}
--------------------------------------------------------------------------------------------------

Based on the cutoff value, all of the patients were dichotomized into either a low value group or a high value group. The clinicopathologic characteristics grouped by D-dimer, GGT and CPDG are summarized in [Table 4](#t0020){ref-type="table"}. Elevated GGT levels were associated with primary sites in the right hemicolon (*P* = .017), preoperative chemotherapy (*P* \< .001), liver metastases in a bilobar distribution (*P* \< .001), diameters of metastases ≥3 cm (*P* = .003) and multiple metastases (*P* \< .001). Elevated D-dimer levels were significantly associated with pre-treatment chemotherapy (*P* \< .001), liver metastases in a bilobar distribution (*P* = .001), multiple metastases (*P* = .004).

Validation of our Findings in an Independent Cohort {#s0070}
---------------------------------------------------

We further verified our findings in the validation set. Elevated D-dimer levels (OR = 4.437, 95%CI: 1.326-14.846, *P* = .016) and GGT levels (OR = 5.156, 95%CI: 1.547-17.184, *P* = .008) were independently associated with major complications in the multivariate analysis ([Table 5](#t0025){ref-type="table"}), in addition to the major resection (OR = 4.310, 95% CI: 4.140-16.294, *P* = .031). The CPDG score was also an independent predictor of major complications. The AUC for the CPDG score was 0.764. This value was associated with a specificity of 0.895 (NPV: 0.791; PPV: 0.467). The AUC for the CPDG score was stronger than the D-dimer levels (AUC: 0.764 versus 0.695) and GGT levels (AUC: 0.764 versus 0.642) for predicting major complications in patients with CRLM after liver resection. In the analysis of survival, elevated D-dimer level (*P* = .007), GGT level (*P* = .007) and CPDG score (*P* \< .001) was associated with decreased PFS ([Figure 3](#f0015){ref-type="fig"}). Analysis of OS was not conducted due to a short follow-up period.Table 5Prognostic factors for major complications in CRLM patients after surgery in the validation set.Table 5FactorUnivariate analysisMultivariate analysis*P*OR (95%CI)*P*Age ≥ 60 years0.077Sex (male vs. female)0.605Preoperative CEA ≥10 ng/ml0.245Major resection0.0074.310 (4.140-16.294)0.031Synchronous metastasis0.0284.637 (0.953-22.562)0.057Primary site Colon0.445Left hemicolon0.446Pretreatment chemotherapy0.004R0 resection0.032Extrahepatic metastases0.861Bilobar distribution0.010Diameter of metastases ≥3 cm0.077Multiple metastases0.060Poorly differentiated0.522T3-T40.835Operation time ≥ 301.5 min\<0.0013.017 (0.878-10.366)0.079D-dimer ≥0.4850.0014.437 (1.326-14.846)0.016GGT ≥35.5 U/L0.0135.156 (1.547-17.184)0.008Heterochronous resection0.083  **The prognostic value on CPDG score**CPDG = 2Reference-CPDG = 121.529 (2.545-\>99)0.005CPDG = 026.060 (2.618-\>99)0.005Figure 3A. OS analysis of D-dimer \<0.285 mg/L versus D-dimer ≥0.285 mg/L in the validation set. B. OS analysis of GGT\<30.5 U/L versus GGT ≥30.5 U/L in the validation set. C. OS analysis of CPDG = 0 versus CPDG =1 versus CPDG = 2 in the validation set.Figure 3

Discussion {#s0075}
==========

To the best of our knowledge, this is the first study to establish a correlation between the outcomes for pre-operative D-dimer levels and GGT levels and the post-operative major complications and survival in patients with CRLM. We found lower pre-operative D-dimer levels and lower pre-operative GGT levels were associated with favorable outcomes, which held true for both post-operative major complications and survival, and then established the CPDG score based on these two biomarkers, as a more accurate prognostic predictor in CRLM patients after resection. Moreover, we have managed to verify the findings in a validation dataset.

The mechanisms of the correlation between elevated D-dimer levels and elevated GGT levels and poor prognoses were unclear. Possible mechanisms are as follows: For the mechanism of D-dimer, the abnormality of hemostasis and fibrinolysis is common in cancer patients, which is related to tumor angiogenesis, invasion, progression and metastatic spread [@bb0105]. As a degradation product of fibrin, an elevated D-dimer level is a signal of the abnormality of hemostasis and fibrinolysis. Besides, some studies revealed that D-dimer affected cellular signaling systems to promote cell proliferation and induce angiogenesis [@bb0160], and induced the growth and spread of tumors by stimulating the cellular adhesion of tumor cells to endothelial cells [@bb0165]. For the mechanism of GGT, GGT is a membrane bound enzyme that is indispensable in GSH metabolism. GSH metabolism is important for protecting cells against oxidants, which is produced during normal metabolism [@bb0055]. However, both GGT and GSH are regularly elevated at the same time in pathological states of oxidative stress, and oxidative stress may be related to oncogenic stimulation [@bb0055], [@bb0170]. In addition, an elevated GGT level plays an important role in carcinogenesis by exerting pro-oxidant effects at both the membrane surface level and the extracellular microenvironment [@bb0175]. However, the specific mechanism needs further exploration.

Previous studies have focused on D-dimer levels and GGT levels in relation to metastatic disease and survival, but have not evaluated post-operative complications. The current study is the first to include complication analyses. For patients with CRLM after resection, our study showed that pre-operative elevated D-dimer levels and elevated GGT levels were associated with major complications. This result may be helpful for clinicians in taking corresponding preventive measures. Some studies have shown an association between post-operative inflammatory markers and post-operative complications in CRLM patients after resection. McCluney et al. [@bb0180] reported that a high NLR on post-operative days 2, 3 and 4 was associated with major complications. Other studies [@bb0185], [@bb0190] have shown that a high post-operative CRP can predict the severity of complications following abdominal surgery. Compared with post-operative inflammatory markers, we advanced the prediction of complications. This could provide clinicians with information at earlier time points, in order to allow for the investigation of patients who may be more likely to develop complications before surgery. Whether the GGT levels and D-dimer levels have a particular utility in detecting a particular type of complication (for example, infective complications or anastomotic complications) is an opportunity for a future prospective study in a larger cohort of CRLM patients after resection.

More recently, elevated D-dimer levels have been found to be associated with poor prognosis in several malignant diseases, including lung cancer, ovarian cancer and gastric cancer [@bb0110], [@bb0115], [@bb0120], [@bb0125], and elevated serum GGT levels have been associated with a worsened prognosis in many cancers, including HCC, renal cell carcinoma and esophageal squamous cell carcinoma [@bb0025], [@bb0070], [@bb0075], [@bb0080]. However, there have been no studies examining the prognostic significance of serum levels of D-dimer and GGT in CRLM after hepatectomy. Our results demonstrated that, in patients with CRLM, compared with pre-operative elevated D-dimer levels and elevated GGT levels, pre-operative decreased D-dimer levels and decreased GGT levels had a better OS, which were consistent with several studies. It is very valuable to be able to predict the prognosis of CRLM patients in the clinic. Some studies have shown that pre-operative inflammatory markers were associated with prognosis in CRLM patients after resection. Giakoustidis et al. [@bb0195] reported that pre-operative elevated NLR in CRLM patients with hepatectomy increased the risk of extrahepatic multifocal recurrence and was an independent predictor of overall survival. Neofytou et al. [@bb0200] identified pre-operative LMR as an independent prognostic factor for PRS, CSS and OS, but not for DFS, in CRLM patients undergoing hepatectomy. Compared with pre-operative inflammatory markers, pre-operative D-dimer levels predict not only survival but also post-operative major complications. We found that the cut-off values of D-dimer levels for predicting survival (0.285 mg/L) and major complications (0.485 mg/L) increased incrementally. It is a possibility for clinicians to tailor CRLM treatment for individual patients before resection, according to the extent of D-dimer elevation.

In this study, we also established the CPDG score construct by D-dimer levels and GGT levels. Interestingly, our results suggested the CPDG score had a stronger prognostic value than either factor alone in the prediction of major complications and survival. It is worth noting that compared with patients with CPDG score = 1 or CPDG score = 0, patients with a CPDG score = 2 (both the D-dimer levels ≥0.285 mg/L and GGT ≥30.5 U/L) had worsened OS. Furthermore, the differences between any two groups were significant. Therefore, the CPDG score possesses both accurate and clinically meaningful prognostic value for CRLM patients after resection. Clinicians can tailor CRLM treatment for individual patients before resection. For example, patients with a CPDG score = 2 represented a high risk of morbidity and mortality. A closer surveillance and certain protective treatments should be offered to these high-risk patients after resection.

Several studies have suggested that GGT levels may be associated with tumor size, tumor number, vascular invasion and TNM stage in several malignancies [@bb0070], [@bb0075], [@bb0080], [@bb0085] and elevated D-dimer levels were demonstrated to be associated with larger tumor, lymph node metastasis, elevated CEA levels and elevated NSE levels [@bb0205], [@bb0210]. In this study, we assessed the association of D-dimer, GGT and CPDG with clinicopathological characteristics in CRLM patients. It is worth mentioning that elevated D-dimer levels and elevated GGT levels were significantly associated with pretreatment chemotherapy, liver metastases in a bilobar distribution and multiple metastases.

We have noticed that the GGT cutoff value and the D-dimer cutoff value in this study were well below the standard reference range, the reasons of which were as follows: Elevated D-dimer is associated with decompensated liver disease, deep venous thrombosis, pulmonary embolism or disseminated intravascular coagulation [@bb0130], [@bb0135]. Elevated serum GGT activity can be found in diseases of the liver, biliary system, and pancreas. It also appears to be related to specific pathologies such as metabolic syndrome, alcohol addiction and chronic liver disease [@bb0090], [@bb0095], [@bb0100]. In clinical settings, GGT is predominantly used as a diagnostic marker for liver disease. If the D-dimer value or GGT value of patients exceed the upper limit of reference range, clinicians would postulate that this patient is at a higher risk of before-mentioned diseases. That is how we define a 'normal range'. However, the outcomes of interest in the current study are the postoperative complications and oncologic outcomes. Patients with GGT value or D-dimer value exceeding cutoffs in this study are thought to be susceptible to worse postoperative and oncologic outcomes, but it did not equal to a higher risk of before-mentioned diseases. In other words, the normal range is defined based on the risk of before-mentioned diseases, whereas the cutoff value in this study is defined based on the risk of worse postoperative and oncologic outcomes. Moreover, the GGT cutoff value and the D-dimer cutoff value largely depend on tumor types and its distribution among patients. Take the HCC for instance, it occurs in the setting of chronic liver inflammation, and is most closely linked to chronic viral hepatitis infection, and thus are frequently associated with elevated GGT value [@bb0080]. Unlike HCC, CRLM is not related to liver disease. Patients who presented with pre-existing comorbidities, known to be related with elevation of GGT, were also excluded in the study. Therefore, nearly three-quarters of the included patients are with a normal GGT value. This is also the reason for why the cutoff value is within the normal range.

Pre-operative D-dimer levels and GGT levels are simple and easily assessable clinical biomarkers for the prognostic stratification of CRLM patients after hepatectomy. However, the findings of the current study should be interpreted within its possible limitations. First, as with a typical retrospective study, our study is limited by biases, such as a lack of random assignment and patient selection. Second, peripheral blood samples were performed only once, which might cause bias. Third, the AUCs of single GGT or D-dimer (0.617 and 0.689, respectively) were relatively low, but it increased to more than 0.7 when combined both, which supported the necessity of a composite scoring system. At last, we only internally validated our findings. Examining the prognostic value of CPDG score in the validation set was not available due to a short follow-up period. Multi-institutional and large prospective studies are needed to confirm our findings and to further explore these results.

In conclusion, the pre-operative D-dimer levels and GGT levels are reliable biomarkers that help in predicting post-operative major complications or survival in CRLM patients after hepatic resection. The CPDG score, which is constructed from the preoperative D-dimer levels and GGT levels, is a more accurate prognostic predictor in CRLM patients after resections.
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